| Outcome Measures: |
Primary: Number of adverse events, Measured as number of events., From time of dosing (day 1) until completion of the follow-up visit (Day 42) | Secondary: For oral cohorts- AUC0-tz,sema,single dose (SD): Area under the semaglutide plasma concentration-time curve from time 0 to tz after a single dose, where tz is the time of last quantifiable concentration, Measured in hours\*nanomoles per liter (h\*nmol/L)., From pre-dose (day 1) to completion of follow-up visit (Day 42)|For oral cohorts- AUC0-infinity (∞),sema,SD: Area under the semaglutide plasma concentration-time curve from time 0 to infinity after a single dose, Measured in hours\*nanomoles per liter (h\*nmol/L)., From pre-dose (day 1) to completion of follow-up visit (Day 42)|For oral cohorts- Cmax,sema,SD: Maximum observed plasma concentration of semaglutide after a single dose, Measured in nanomoles per liter (nmol/L)., From pre-dose (day 1) to completion of follow-up visit (day 42)|For oral cohorts- tmax,sema,SD: Time to maximum observed concentration of semaglutide after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of follow-up visit (day 42)|For oral cohorts- t½,sema,SD: Terminal half-life of semaglutide after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of follow-up visit (day 42)|For oral cohorts- AUC0-tz,6856,SD: Area under the NNC0113-6856 plasma concentration-time curve from time 0 to tz after a single dose, where tz is the time of last quantifiable concentration, Measured in hours\*nanomoles per liter (h\*nmol/L)., From pre-dose (day 1) to completion of visit 5 (day 22)|For oral cohorts- AUC0-∞,6856,SD: Area under the NNC0113-6856 plasma concentration-time curve from time 0 to infinity after a single dose, Measured as hours\*nanomoles per liter (h\*nmol/L)., From pre-dose (day 1) to completion of visit 5 (day 22)|For oral cohorts- Cmax,6856,SD: Maximum observed plasma concentration of NNC0113-6856 after a single dose, Measured as nanomoles per liter (nmol/L)., From pre-dose (day 1) to completion of visit 5 (day 22)|For oral cohorts- tmax,6856,SD: Time to maximum observed concentration of NNC0113-6856 after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For oral cohorts- t½,6856,SD: Terminal half-life of NNC0113-6856 after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For oral cohorts- AUC0-tz,4768,SD: Area under the NNC0113-4768 plasma concentration-time curve from time 0 to tz after a single dose, where tz is the time of last quantifiable concentration, Measured in hours\*nanomoles per liter (h\*nmol/L)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For oral cohorts- AUC0-∞,4768,SD: Area under the NNC0113-4768 plasma concentration-time curve from time 0 to infinity after a single dose, Measured in hours\*nanomoles per liter (h\*nmol/L)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For oral cohorts- Cmax,4768,SD: Maximum observed plasma concentration of NNC0113-4768 after a single dose, Measured in nanomoles per liter (nmol/L)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For oral cohorts- tmax,4768,SD: Time to maximum observed concentration of NNC0113-4768 after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For oral cohorts- t½,4768,SD: Terminal half-life of NNC0113-4768 after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For intravenous (i.v.) cohort- AUC0-infinity (∞),sema,SD: Area under the semaglutide plasma concentration-time curve from time 0 to infinity after a single dose, Measured in hours\*nanomoles per liter (h\*nmol/L)., From pre-dose (day 1) to completion of follow-up visit (day 42)|For i.v. cohort- t½,sema,SD: Terminal half-life of semaglutide after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of follow-up visit (day 42)|For i.v. cohort- Cmax,sema,SD: Maximum observed plasma concentration of semaglutide after a single dose, Measured in nanomoles per liter (nmol/L)., From pre-dose (day 1) to completion of follow-up visit (day 42)|For i.v. cohort- AUC0-∞,6856,SD: Area under the NNC0113-6856 plasma concentration-time curve from time 0 to infinity after a single dose, Measured as hours\*nanomoles per liter (h\*nmol/L), From pre-dose (day 1) to completion of visit 5 (day 22)|For i.v. cohort- t½,6856,SD: Terminal half-life of NNC0113-6856 after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of visit 5 (day 22)|For i.v. cohort- CL6856,SD: Total plasma clearance of NNC0113-6856 after a single dose, Measured in liters per hour (L/h)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For i.v. cohort- Vz6856,SD: Apparent volume of distribution of NNC0113-6856 after a single dose based on plasma concentration values, Measured in liters (L)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For i.v. cohort- MRT6856,SD: Mean residence time for NNC0113-6856 after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For i.v. cohort- AUC0-infinity (∞),4768,SD: Area under the NNC0113-4768 plasma concentration-time curve from time 0 to infinity after a single dose, Measured in hours\*nanomoles per liter (h\*nmol/L)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For i.v. cohort- t½,4768,SD: Terminal half-life of NNC0113-4768 after a single dose, Measured in hours (h)., From pre-dose (day 1) to completion of visit 5 (Day 22)|For i.v. cohort and oral cohort- AUC0-∞,6856,SD/dose: Area under the NNC0113-6856 plasma concentration-time curve from 0 to infinity after a single dose divided by the dose administered, Measured in hours\*nanomoles per liter per milligram (h\*nmol/L/mg)., From pre-dose (day 1) to completion of visit 5 (Day 22)
|
